Encounter Resources EBITDA margin
Cos'è EBITDA margin di Encounter Resources?
EBITDA margin di Encounter Resources Limited è -332.24%
Qual è la definizione di EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin di aziende nel Materials settore su ASX rispetto a Encounter Resources
Cosa fa Encounter Resources?
Encounter Resources Limited engages in the exploration and development of mineral deposits in Australia. It explores for zinc, copper, gold, and cobalt deposits. The company holds interests in the Lamil and Yeneena projects located in the Paterson Province, Western Australia. It also holds interests in the Aileron project situated in the West Arunta, Western Australia; and the Elliott copper project located in the Northern Territory. The company was incorporated in 2004 and is based in Subiaco, Australia.
Aziende con ebitda margin simili a Encounter Resources
- Forbidden Spirits Distilling ha EBITDA margin di -336.58%
- European Metals ha EBITDA margin di -334.90%
- Carmat SA ha EBITDA margin di -333.29%
- La Jolla Pharmaceutical Co ha EBITDA margin di -333.27%
- Mabpharm ha EBITDA margin di -332.56%
- Elsight ha EBITDA margin di -332.42%
- Encounter Resources ha EBITDA margin di -332.24%
- Microba Life Sciences Ltd ha EBITDA margin di -331.80%
- Global Blood Therapeutics ha EBITDA margin di -330.50%
- Sienna Cancer Diagnostics ha EBITDA margin di -330.16%
- Nova Royalty ha EBITDA margin di -330.11%
- Vermillion ha EBITDA margin di -329.33%
- Clearside Biomedical Inc ha EBITDA margin di -329.31%